⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369237 | 1.00 | — | — | |
| SCHEMBL15341654 | 0.81 | — | — | |
| SCHEMBL12241744 | 0.81 | — | — | |
| SCHEMBL9604976 | 0.81 | — | — | |
| SCHEMBL10200821 | 0.75 | — | — | |
| SCHEMBL2808933 | 0.73 | — | — | |
| SCHEMBL1770651 | 0.73 | — | — | |
| SCHEMBL22984154 | 0.69 | — | — | |
| SCHEMBL20055507 | 0.69 | — | — | |
| SCHEMBL12444210 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013111158-A2 | PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR | MSN LABORATORIES LIMITED (IN) | 2013-08-01 | — | — | WO | claimed |
| WO-2026103846-A1 | CYCLIC COMPOUND AND PREPARATION THEREFOR AND PHARMACEUTICAL USE THEREOF | 山东先声再明生物制药有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-4558507-B1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
| EP-4696316-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042740-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4054719-B1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688156-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-5610141-A | CELL DIVISION STIMULANT | NYCOMED IMAGING AS (NO) | 1997-03-11 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0673388-A1 | DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-09-27 | — | — | EP | disclosed |
| EP-0643725-A1 | SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | NYCOMED IMAGING AS (NO) | 1995-03-22 | — | — | EP | disclosed |
| EP-0624163-A1 | CYCLIC CALCITONIN DERIVATIVES AND METHOD FOR THEIR PRODUCTION | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1994-11-17 | — | — | EP | disclosed |
| CN-1086221-A | Peptide compounds | HAFSLUND NYCOMED AS (NO) | 1994-05-04 | — | — | CN | disclosed |
| WO-1993024524-A1 | SINGLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | HAFSLUND NYCOMED AS (NO) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024523-A1 | DOUBLE CHAIN PEPTIDE COMPOUNDS HAVING HEMOREGULATORY ACTIVITY | HAFSLUND NYCOMED AS (NO) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993015106-A1 | CYCLIC CALCITONINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1993-08-05 | — | — | WO | disclosed |
| US-4847287-A | Pure enantiomers of 4,5-disubstituted gamma-butyrolactams, and their use as antiamnestic agents | BAYER AG (DE) | 1989-07-11 | — | — | US | disclosed |